Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$31.76
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.64%
Accommodative
10-Year Treasury
4.32%
2026-04-01
Unemployment
4.3%
Near full employment
CPI Index
332.4
2026-04-01
M2 Money Supply
$22.8T
2026-04-01
The Federal Funds rate stands at 3.64% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.32%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.3%; Industrial production index is at 102.5; M2 money supply is $22.8T; CPI index stands at 332.4.
SWOT Analysis — PAHC
Inflationary BoomStrengths
Net Income: $48.3M (+1897.7% YoY) — Profit grew 1898% — the company kept more of each dollar earned.
EPS (Diluted): $1.19 (+1883.3% YoY) — Earnings per share rose 1883% — each share earned more.
Total Assets: $1.4B (+38.6% YoY) — Total assets grew 39% — the company's resource base expanded.
Gross Profit: $399.9M (+27.7% YoY) — Gross profit rose 28% — the spread between revenue and direct costs improved.
Weaknesses
Operating Cash Flow: $80.1M (-8.5% YoY) — Operating cash flow fell 9% but remained positive.
Opportunities
No clear opportunities identified at this time.
Threats
Total liabilities represent 79% of total assets — elevated leverage that amplifies both gains and losses.
Financial Charts
Revenue vs Net Income
Gross Profit vs Operating Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
Net Income
$48.3M
was $2.4M
Profit grew 1898% — the company kept more of each dollar earned.
EPS (Diluted)
$1.19
was $0.06
Earnings per share rose 1883% — each share earned more.
Total Assets
$1.4B
was $982.2M
Total assets grew 39% — the company's resource base expanded.
Gross Profit
$399.9M
was $313.1M
Gross profit rose 28% — the spread between revenue and direct costs improved.
Operating Cash Flow
$80.1M
was $87.6M
Operating cash flow fell 9% but remained positive.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Total liabilities represent 79% of total assets — elevated leverage that amplifies both gains and losses.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade PAHC
Links open broker research pages. Not an endorsement or recommendation.
Research Phibro Animal Health Corporation
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.